Vivreon Biosciences Investor Presentation July 2021

Vivreon Biosciences presents its dual-acting kappa and mu receptor agonist platform with lead candidate in clinical development for pruritus and cough indications. The company highlights statistically significant pruritus reduction data and near-term Phase 2b/3 and Phase 2a topline data expected in H1 2022 for prurigo nodularis and IPF.